Department of Pediatric Neurology, Karadeniz Technical University Faculty of Medicine, 61080 Trabzon, Turkey.
Eur J Paediatr Neurol. 2011 Nov;15(6):527-31. doi: 10.1016/j.ejpn.2011.05.004. Epub 2011 Jun 23.
The aim of this study was to investigate whether oxcarbazepine (OXC) monotherapy causes weight gain in epileptic children.
A total of 22 children with epilepsy (age 3.0-16.4 years) were assigned to OXC therapy. Serum levels of glucose, insulin, cortisol, leptin, neuropeptide Y (NPY), galanin and ghrelin were assessed before OXC therapy (month 0) and after the 6th and 18th months.
There was no statistically significant difference in weight-standard deviation score (SDS), Height-SDS, BMI-SDS, serum glucose, insulin, cortisol, leptin, NPY, galanin and ghrelin levels between initial values (month 0) and those in the 6th and 18th months after OXC therapy (p > 0.05).
Our results indicate that OXC therapy causes neither weight change nor alterations in serum glucose, insulin, cortisol, leptin, NPY, galanin and ghrelin levels in children with epilepsy.
本研究旨在探讨单药奥卡西平（OXC）治疗是否会导致癫痫儿童体重增加。
共 22 例癫痫患儿（年龄 3.0-16.4 岁）接受 OXC 治疗。在 OXC 治疗前（第 0 个月）和治疗后第 6 个月和第 18 个月，评估血清葡萄糖、胰岛素、皮质醇、瘦素、神经肽 Y（NPY）、甘丙肽和胃饥饿素水平。
体重标准差评分（SDS）、身高 SDS、BMI-SDS、血清葡萄糖、胰岛素、皮质醇、瘦素、NPY、甘丙肽和胃饥饿素水平在初始值（第 0 个月）和 OXC 治疗后第 6 个月和第 18 个月之间无统计学差异（p>0.05）。
我们的结果表明，OXC 治疗不会导致癫痫儿童体重变化，也不会改变血清葡萄糖、胰岛素、皮质醇、瘦素、NPY、甘丙肽和胃饥饿素水平。
